CC
LCTX icon

CQS Cayman’s Lineage Cell Therapeutics LCTX Stock Holding History

CQS Cayman’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-170,191
Closed -$683K – 200
2015
Q1 		$683K Buy
+170,191
New +$589K 0.03% 177

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CQS Cayman's LCTX Position: Q2 2015 in Review

CQS Cayman sold out of Lineage Cell Therapeutics (LCTX) in Q2 2015, closing a stake of 170,191 shares — an estimated $683K sold.

CQS Cayman first reported a position in LCTX in Q1 2015 and held it in 1 quarter. The position peaked at $683K in Q1 2015. 80 funds tracked by Wall St. Rank hold LCTX as of Q2 2015.

  • CQS Cayman reported no remaining Lineage Cell Therapeutics position as of Q2 2015 after selling out during the quarter.
  • CQS Cayman sold 170,191 Lineage Cell Therapeutics shares in Q2 2015, an estimated $683K.
  • CQS Cayman first reported a position in Lineage Cell Therapeutics in Q1 2015 and held it in 1 quarter.
  • CQS Cayman's Lineage Cell Therapeutics position peaked at $683K in Q1 2015.
  • 80 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2015.

Based on CQS Cayman's 13F filing for Q2 2015, filed 12 Aug 2015.